Altimmune
ALT
23 hedge funds and large institutions have $1.66M invested in Altimmune in 2018 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 5 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
92% more capital invested
Capital invested by funds: $867K → $1.66M (+$797K)
44% more funds holding
Funds holding: 16 → 23 (+7)
6.97% more ownership
Funds ownership: 2.25% → 9.22% (+7%)
55% less call options, than puts
Call options by funds: $63K | Put options by funds: $139K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$842K |
| 2 |
Renaissance Technologies
New York
|
+$539K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$391K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$300K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$219K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$408K |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$220K |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$14K |
| 4 |
Morgan Stanley
New York
|
-$13.7K |
ALT Hedge Fund Activity: Q4 2018 in Review
23 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q4 2018, worth a combined $1.66M — up 92% from $867K a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ALT positions and 5 closed out — a net gain of 7 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $842K. The largest seller was CVI Holdings, exiting entirely with an estimated $408K sold.
- 23 institutional investors held Altimmune (ALT) as of Q4 2018, up from 16 in Q3 2018.
- Funds reported $1.66M of Altimmune stock for Q4 2018, up 92% quarter-over-quarter.
- 12 funds opened new Altimmune positions in Q4 2018 and 5 closed out, a net change of +7 holders.
- The largest Altimmune buyer in Q4 2018 was Sabby Management, an estimated $842K added.
- The largest Altimmune seller in Q4 2018 was CVI Holdings, an estimated $408K sold.
Based on aggregated 13F filings for Q4 2018.